Login to Your Account

'Surprise' Bydureon Thumbs Up in Europe; Amylin Shares Rise

By Jennifer Boggs

Monday, April 18, 2011
Bydureon watchers finally got some good news, as the European Committee for Medicinal Products for Human Use (CHMP) voted in favor of the once-weekly version of glucagon-like peptide-1 agonist exenatide in Type II diabetes, all but ensuring the drug's final approval overseas.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription